What are the indications for Ripotinib?

Repotrectinib is a new type of oral targeted drug that is a multi-target tyrosine kinase inhibitor (TKI). It is specially designed to solve the treatment bottleneck caused by traditional TKI resistance or mutations in patients with known gene fusion tumors. The biggest highlight of this drug is its highly selective and penetrating molecular structure, which can accurately target multiple driver mutations. It is especially suitable for tumor types caused by ROS1 and NTRK gene fusion. It is currently one of the most cutting-edge precision treatment drugs in the world.

The first and main indication is the treatment of patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC). Lung cancer driven by ROS1 fusion genes is a rare subtype but is generally more common in younger, non-smoking people. Ripotinib has excellent central nervous system penetration ability for this subtype, and is expected to control common refractory problems such as brain metastasis, especially providing a new option for patients who are resistant to first-generation ROS1 inhibitors such as crizotinib.

Secondly, repotinib is also approved for the treatment of solid tumors with neurotrophic tyrosine receptor kinase (NTRK) gene fusions. NTRK fusion can appear in a variety of solid tumors, including infantile fibrosarcoma, thyroid cancer, pancreatic cancer and even breast cancer. Although the incidence is low, it is highly targetable as a main driver. Ripotinib's targets include TRKA, TRKB, and TRKC, and it can effectively deal with drug-resistant mutations generated after NTRK inhibitors, especially in the context of known drug-resistant mutations such as NTRK G595R and G667C, it still maintains good activity.

The drug has been approved in many places such as Europe and the United States. It is suitable for NTRK fusion tumors in children and adults aged 12 years and above. The treatment options for this group of people have been extremely limited before, especially in pediatric patients, there is a lack of effective targeted solutions. With its smaller molecular structure, excellent penetrability and cross-mutation spectrum activity, Ripotinib brings hope to these patients and also indicates that the general trend of "gene-led tumor treatment" is gradually taking shape.

Reference materials:https://www.drugs.com/mtm/repotrectinib.html